Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can Hands-On chest therapy loosen breathing? trial puts it to the test

NCT ID NCT07822139

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at Karabuk University are testing whether integrated myofascial release therapy, a hands-on manual technique, changes breathing-related measures in healthy adults. Forty participants receive 12 sessions over 6 weeks, with each session targeting the neck, shoulders, and chest. The team measures lung function, cough strength, and chest expansion before treatment, right after the first session, at the end of 6 weeks, and again 1 and 3 months later. The goal is to see whether a single session has an immediate effect and whether repeated sessions produce changes that last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
integrated myofascial release therapy, a hands-on manual technique
What this could lead to
If it works, this could support a low-cost, drug-free way to improve chest mobility and breathing mechanics in healthy adults, and point toward testing it in people with lung conditions.
What could go wrong
The study is small, with 40 healthy volunteers, and any changes in breathing tests may be modest or fade after treatment stops. Manual therapy can cause temporary soreness, and results in healthy adults may not carry over to people with lung disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Ability to communicate in Turkish. * Voluntary agreement to participate in the study. * Ability to attend the scheduled assessment and treatment sessions regularly. Exclusion Criteria: * Asthma, clinically significant dyspnea, or chronic pulmonary disease. * Influenza, COVID-19, or another acute respiratory tract infection within the previous 6 weeks that may affect respiratory function. * Recent surgery involving the neck, shoulder, or thoracic region. * History of rib fracture or an acute musculoskeletal condition that would make manual therapy inappropriate. * Serious cardiovascular, neurological, or systemic disease that could prevent safe participation in the assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Respiratory Aspiration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karabuk University

    Karabük, Karabük Province, 78050, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.